Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen
- PMID: 23056181
- PMCID: PMC3462800
- DOI: 10.1371/journal.pone.0044631
Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen
Abstract
Studies into the genetic origins of tumor cell chemoactivity pose significant challenges to bioinformatic mining efforts. Connections between measures of gene expression and chemoactivity have the potential to identify clinical biomarkers of compound response, cellular pathways important to efficacy and potential toxicities; all vital to anticancer drug development. An investigation has been conducted that jointly explores tumor-cell constitutive NCI60 gene expression profiles and small-molecule NCI60 growth inhibition chemoactivity profiles, viewed from novel applications of self-organizing maps (SOMs) and pathway-centric analyses of gene expressions, to identify subsets of over- and under-expressed pathway genes that discriminate chemo-sensitive and chemo-insensitive tumor cell types. Linear Discriminant Analysis (LDA) is used to quantify the accuracy of discriminating genes to predict tumor cell chemoactivity. LDA results find 15% higher prediction accuracies, using ∼30% fewer genes, for pathway-derived discriminating genes when compared to genes derived using conventional gene expression-chemoactivity correlations. The proposed pathway-centric data mining procedure was used to derive discriminating genes for ten well-known compounds. Discriminating genes were further evaluated using gene set enrichment analysis (GSEA) to reveal a cellular genetic landscape, comprised of small numbers of key over and under expressed on- and off-target pathway genes, as important for a compound's tumor cell chemoactivity. Literature-based validations are provided as support for chemo-important pathways derived from this procedure. Qualitatively similar results are found when using gene expression measurements derived from different microarray platforms. The data used in this analysis is available at http://pubchem.ncbi.nlm.nih.gov/andhttp://www.ncbi.nlm.nih.gov/projects/geo (GPL96, GSE32474).
Conflict of interest statement
Figures
Similar articles
-
Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays.Mol Cancer Ther. 2005 Mar;4(3):399-412. doi: 10.1158/1535-7163.MCT-04-0234. Mol Cancer Ther. 2005. PMID: 15767549
-
Linking tumor cell cytotoxicity to mechanism of drug action: an integrated analysis of gene expression, small-molecule screening and structural databases.Proteins. 2005 May 15;59(3):403-33. doi: 10.1002/prot.20392. Proteins. 2005. PMID: 15778971 Review.
-
Gene expression analysis in clear cell renal cell carcinoma using gene set enrichment analysis for biostatistical management.BJU Int. 2011 Jul;108(2 Pt 2):E29-35. doi: 10.1111/j.1464-410X.2010.09794.x. Epub 2011 Mar 16. BJU Int. 2011. PMID: 21435154
-
Data Mining Approaches for Genomic Biomarker Development: Applications Using Drug Screening Data from the Cancer Genome Project and the Cancer Cell Line Encyclopedia.PLoS One. 2015 Jul 1;10(7):e0127433. doi: 10.1371/journal.pone.0127433. eCollection 2015. PLoS One. 2015. PMID: 26132924 Free PMC article.
-
Design, synthesis and anticancer activity against the MCF-7 cell line of benzo-fused 1,4-dihetero seven- and six-membered tethered pyrimidines and purines.Curr Med Chem. 2008;15(25):2614-31. doi: 10.2174/092986708785909021. Curr Med Chem. 2008. PMID: 18855682 Review.
Cited by
-
Bidirectional Genetic Control of Phenotypic Heterogeneity and Its Implication for Cancer Drug Resistance.Mol Biol Evol. 2021 May 4;38(5):1874-1887. doi: 10.1093/molbev/msaa332. Mol Biol Evol. 2021. PMID: 33355660 Free PMC article.
-
ToxRefDB version 2.0: Improved utility for predictive and retrospective toxicology analyses.Reprod Toxicol. 2019 Oct;89:145-158. doi: 10.1016/j.reprotox.2019.07.012. Epub 2019 Jul 21. Reprod Toxicol. 2019. PMID: 31340180 Free PMC article.
-
Current dichotomy between traditional molecular biological and omic research in cancer biology and pharmacology.World J Clin Oncol. 2015 Dec 10;6(6):184-8. doi: 10.5306/wjco.v6.i6.184. World J Clin Oncol. 2015. PMID: 26677427 Free PMC article.
-
Using drug response data to identify molecular effectors, and molecular "omic" data to identify candidate drugs in cancer.Hum Genet. 2015 Jan;134(1):3-11. doi: 10.1007/s00439-014-1482-9. Epub 2014 Sep 12. Hum Genet. 2015. PMID: 25213708 Free PMC article. Review.
-
PubChem applications in drug discovery: a bibliometric analysis.Drug Discov Today. 2014 Nov;19(11):1751-1756. doi: 10.1016/j.drudis.2014.08.008. Epub 2014 Aug 27. Drug Discov Today. 2014. PMID: 25168772 Free PMC article. Review.
References
-
- Teicher BA, Andrews PA (2010) Anticancer drug development guide preclinical screening, clinical trials, and approval. Totowa, N.J.: Humana Press.
-
- Yap TA, Sandhu SK, Workman P, de Bono JS (2010) Envisioning the future of early anticancer drug development. Nat Rev Cancer 10: 514–523. - PubMed
-
- Wilson TR, Johnston PG, Longley DB (2009) Anti-apoptotic mechanisms of drug resistance in cancer. Curr Cancer Drug Targets 9: 307–319. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources